Vigil Neuroscience Company Leadership
| VIGL Stock | USD 2.67 0.13 5.12% |
Vigil Neuroscience's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Vigil Neuroscience suggests that most insiders are extremely bullish. Vigil Neuroscience employs about 66 people. The company is managed by 19 executives with a total tenure of roughly 154 years, averaging almost 8.0 years of service per executive, having 3.47 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-12-19 | Haeberlein Samantha L Budd | Acquired 12000 @ 1.71 | View | ||
| 2024-12-18 | Ivana Magovcevic-Liebisch | Acquired 5000 @ 1.67 | View | ||
| 2024-12-05 | Ivana Magovcevic-Liebisch | Acquired 5000 @ 2.34 | View |
Monitoring Vigil Neuroscience's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Vigil |
Vigil Neuroscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.3806) % which means that it has lost $0.3806 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7362) %, meaning that it created substantial loss on money invested by shareholders. Vigil Neuroscience's management efficiency ratios could be used to measure how well Vigil Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.55. The value of Return On Capital Employed is expected to slide to -0.83. At this time, Vigil Neuroscience's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 22.9 M this year, although the value of Other Current Assets will most likely fall to about 2.7 M.The value of Common Stock Shares Outstanding is expected to slide to about 27.6 M. The value of Net Loss is expected to slide to about (64.5 M)
Vigil Neuroscience Workforce Comparison
Vigil Neuroscience is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,247. Vigil Neuroscience holds roughly 66.0 in number of employees claiming about 5% of equities under Health Care industry.
Vigil Neuroscience Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vigil Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vigil Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vigil Neuroscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 1.25 | 35 | 28 | 1,802,385 | 1,675,909 |
| 2022-12-01 | 0.5 | 1 | 2 | 300.00 | 600.00 |
| 2022-03-01 | 0.9429 | 33 | 35 | 29,225,766 | 37,917,838 |
Vigil Neuroscience Notable Stakeholders
A Vigil Neuroscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vigil Neuroscience often face trade-offs trying to please all of them. Vigil Neuroscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vigil Neuroscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ivana JD | CEO President | Profile | |
| Sharon Morani | Director Operations | Profile | |
| MS MBA | VP Development | Profile | |
| M MBA | VP Development | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Spyridon MD | Chief Officer | Profile | |
| Weeteck Yeo | Senior Operations | Profile | |
| Jessica PMP | Senior Management | Profile | |
| Mr DABT | Senior Development | Profile | |
| Christopher JD | General Secretary | Profile | |
| Park CPA | Accounting Manager | Profile | |
| Jennifer CPA | Chief Officer | Profile | |
| Kelly Neelon | Vice Operations | Profile | |
| Charles Maggs | Head FPA | Profile | |
| Eric Brophy | Senior Technology | Profile | |
| Sarah Carmody | VP Communications | Profile | |
| David Gray | Chief Officer | Profile | |
| Leah Gibson | Vice Communications | Profile | |
| Christian Mirescu | Senior Neuroimmunology | Profile |
About Vigil Neuroscience Management Performance
The success or failure of an entity such as Vigil Neuroscience often depends on how effective the management is. Vigil Neuroscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vigil management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vigil management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.82) | (0.78) |
Vigil Neuroscience Workforce Analysis
Traditionally, organizations such as Vigil Neuroscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vigil Neuroscience within its industry.Vigil Neuroscience Manpower Efficiency
Return on Vigil Neuroscience Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 4.3M | |
| Working Capital Per Employee | 1.7M | |
| Working Capital Per Executive | 5.8M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.